Organisation paid for research Program year 2025 Source: CMS Open Payments

Southeastern Research Center

Neither a doctor nor a teaching hospital

Research payments

$2,642,753

1,465 payments

Through program year 2025, Southeastern Research Center is reported as receiving $2,642,753 in research payments, across 1,465 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$345,730	225
2024	Research	$706,534	469
2023	Research	$636,560	165
2022	Research	$537,298	256
2021	Research	$190,291	206
2020	Research	$210,753	122
2019	Research	$15,587	22

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $667,216 116 payments
Genentech, Inc. $391,054 200 payments
United Therapeutics Corporation $274,560 84 payments
Hoffmann-La Roche Limited $234,145 65 payments
GlaxoSmithKline, LLC. $187,094 103 payments
CSL Behring $185,781 79 payments
Insmed, Inc. $135,673 507 payments
Chiesi USA, Inc. $124,893 36 payments
Mylan Specialty L.P. $99,972 11 payments
Amgen Inc. $75,300 4 payments

Studies the money was for Research payments · program years 2019–2025

PH Iib of Astegolimab in COPD $482,229 177 payments
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $192,128 59 payments
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis $185,781 79 payments
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $151,917 78 payments
PDE4 Phase III trial in IPF patients $151,343 30 payments
Phase 2 Double Blind Randomized Study in IPF and SSc ILD $132,330 11 payments
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) $89,607 58 payments
Tio & Olo versus PBO stratified by PIFR $79,028 4 payments
PDE4 Phase III trial in PF ILD $77,875 3 payments
Phase II PoCP $73,987 69 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.